Sharon Iyobor Igbinoba

Sharon Iyobor Igbinoba

Auto-generated profile, based on publicly available information

Sharon Iyobor Igbinoba

Department of Clinical Pharmacy and Pharmacy Administration, Obafemi Awolowo University, Ile-Ife, Nigeria

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Journal of Herbmed Pharmacology
Verified
Journal Article
Open access
PDF file
AAAdebanjo Adegbola
Adebanjo Adegbola
SISharon Iyobor Igbinoba
Sharon Iyobor Igbinoba
SASa'AD Toyin Abdullahi
Sa'AD Toyin Abdullahi
JSJulius Olugbenga Soyinka
Julius Olugbenga Soyinka
COCyprian Ogbona Onyeji
Cyprian Ogbona Onyeji
Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) constitutes a source of great concern to health authorities worldwide. Herbal medicinal products are used as a significant treatment option for highly active antiretroviral therapies, the efficacies of which are negatively impacted by the emergence of multidrug-resistant strains to the recommended treatment guidelines. This review provides an updated synopsis of available documents on herbal medicinal products with anti-HIV activities. Concurrent consumption of herbal products with conventional drugs, which is often necessitated by co-morbidity of HIV with other diseases, can potentially alter the pharmacokinetics of the co-administered orthodox drugs. Phytochemical constituents of the herbal medicinal products with antiretroviral activities were identified, and their potential to mediate pharmacokinetic changes through modulation of drug-metabolizing enzymes and P-glycoprotein was reported. Herb-drug interactions (HDIs) that can result in significant adverse effects were also discussed with documenting the information for the therapeutic utility of these clinically effective antiretroviral herbal medicinal products with potential for development into newer anti-HIV drugs.

1 March 2026 in Drug Metabolism and Bioanalysis
Verified
Journal Article
Closed access
SISharon Iyobor Igbinoba
Sharon Iyobor Igbinoba
COCyprian Ogbonna Onyeji
Cyprian Ogbonna Onyeji
AAAdebanjo Adegbola
Adebanjo Adegbola
AAAdebusuyi Akande Ademisoye
Adebusuyi Akande Ademisoye
JSJulius Olugbenga Soyinka
Julius Olugbenga Soyinka
Introduction: Hypertension is one of the most common non-communicable diseases, and reports indicate that its prevalence is escalating globally due to several factors. Studies in different countries have shown an upsurge in the use of Herbal Medicinal Products (HMPs), including herbal antihypertensive medicines taken by people with hypertension, and 20-80 % of hypertensive patients concurrently use these herbal medicines and conventional antihypertensive medicines or other drugs. The safety and efficacy of the concurrent use of herbal and orthodox medicines are of great concern because of the high possibility of herb-drug interactions. Methods: An extensive literature search was undertaken, and the information obtained was subjected to critical analysis. This review aimed to update the available data on HMPs with reproducible evidence-based antihypertensive efficacies. Additionally, the major phytochemical and bioactive constituents of these HMPs were identified along with a discussion of their potential to modulate activities of drug-metabolizing enzymes and drug transport systems, especially Pglycoprotein. Results: More than 50 commonly used medicinal plants from different regions of the world have been documented for their anti-hypertensive activity. Most of these studies used animal models to authenticate the antihypertensive activities of the herbs. In contrast, a few studies on extracts of Hibiscus sabdariffa, Allium sativum, Apium graveolens, Nigella sativa, Linum usitatissimum, and Camellia sinensis involved clinical trials. Potentials for herb-drug interactions varied among the clinically effective HMPs due to the wide variability in their phytochemical constituents. Conclusion: Safety issues in using these HMPs were highlighted by the identification of beneficial or adverse, clinically significant herb-drug interactions.